N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms

Table 1 Study Assessments and Timeline

		0 week	2, 4 & 6 w	8 weeks	24 weeks	52 weeks
General	Demographic questionnaire	X		X¹	X³	X³
Diagnosis	MINI	X
Symptoms	Interview to rate PANSS and CAINS	X		X	X	X
Symptoms	Calgary depression scale for schizophrenia (CDSS) combined with the Montgomery Asberg Depression Scale (MADRS)	X		X	X	X
Safety	Adverse symptoms checklist (SAFTEE)	X	X²	X	X	X
	ECG	X				X
	Blood test for clozapine monitoring	X		X	X	X
QoL	Manchester Quality of Life Scale (MANSA)	X		X	X	X
QoL	Assessment of Quality of Life (AQoL)	X		X	X	X
Cognition	The Wechsler test of adult reading (WTAR): Premorbid IQ	X
	Wechsler abbreviated scale of IQ (WASI): Current IQ	X		X	X	X
	MATRICS	X		X	X	X
Biomarkers	Blood sample for biomarkers	X		X	X	X
Neuro-imaging³	Magnetic resonance spectroscopy (MRS)	X		X		X

¹Shortened version to note for changes in work, study, living arrangements
²Telephone safety check
³Only participants who are in the Melbourne arm and provide informed consent for the imaging component will be administered these additional assessments

ISSN: 1471-244X